Browsing by Author "O'Shea, John J."

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells
    (The American Association of Immunologists, 2015-04-15) Richard, Arianne C.; Tan, Cuiyan; Hawley, Eric T.; Gomez-Rodriguez, Julio; Goswami, Ritobrata; Yang, Xiang-ping; Cruz, Anthony C.; Penumetcha, Pallavi; Hayes, Erika T.; Pelletier, Martin; Gabay, Odile; Walsh, Matthew; Ferdinand, John R.; Keane-Myers, Andrea; Choi, Yongwon; O'Shea, John J.; Al-Shamkhani, Aymen; Kaplan, Mark H.; Gery, Igal; Siegel, Richard M.; Meylan, Françoise; Department of Pediatrics, School of Medicine
    The TNF family cytokine TL1A (Tnfsf15) costimulates T cells and type 2 innate lymphocytes (ILC2) through its receptor DR3 (Tnfrsf25). DR3-deficient mice have reduced T cell accumulation at the site of inflammation and reduced ILC2-dependent immune responses in a number of models of autoimmune and allergic diseases. In allergic lung disease models, immunopathology and local Th2 and ILC2 accumulation is reduced in DR3-deficient mice despite normal systemic priming of Th2 responses and generation of T cells secreting IL-13 and IL-4, prompting the question of whether TL1A promotes the development of other T cell subsets that secrete cytokines to drive allergic disease. In this study, we find that TL1A potently promotes generation of murine T cells producing IL-9 (Th9) by signaling through DR3 in a cell-intrinsic manner. TL1A enhances Th9 differentiation through an IL-2 and STAT5-dependent mechanism, unlike the TNF-family member OX40, which promotes Th9 through IL-4 and STAT6. Th9 differentiated in the presence of TL1A are more pathogenic, and endogenous TL1A signaling through DR3 on T cells is required for maximal pathology and IL-9 production in allergic lung inflammation. Taken together, these data identify TL1A-DR3 interactions as a novel pathway that promotes Th9 differentiation and pathogenicity. TL1A may be a potential therapeutic target in diseases dependent on IL-9.